| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > Strong Leadership Builds on a Bedrock of Strong Values |
|
Digg It - Strong Leadership Builds on a Bedrock of Strong Values
"Values are the bedrock of any corporate culture. As the essence of a company's philosophy for achieving success, values provide a sense of common direction for all employees and guidelines for day-to-day behavior...ofte According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product n companies succeed because their employees can identify, embrace, and act on the values of the organization." — Terrence Deal and Allan Kennedy, Corporate Cultures: The Rites and Rituals of Corporate Life Early in my c ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in areer I found work that was a great fit for my skills and interests. I grew and moved through the company to ever-higher levels of responsibility. I was especially lucky to be mentored by a senior manager who coached and lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. developed my skills, and brought out more potential in me than I realized I had at the time. Her trust and faith in me built my confidence and a strong foundation for future growth. After one promotion that would take here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe e across the country to manage the company's largest branch, I spent a week introducing John, the new president (he was also new to me, since he came from another part of the company), to the various field managers I ser d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ved and supported with my internal training and consulting work. It quickly became embarrassing to be with him. He was an obnoxious boor who had all the answers – often to questions he wasn't even asked. His personal ti ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc me management was a joke. One morning, at the time we were to leave for a meeting, I had to rouse him from bed by pounding on his hotel room door (he'd been "out on the town" the night before). His honesty and ethics wer easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi e questionable,...and he was an elitist who treated front line team members as "the little people." I subsequently moved 2,000 miles away from him and head office to assume new responsibilities at one of our branch offi nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically es. Since he was clearly an out-of-sight-out-of-mind manager I was thankful for the distance that separated us. But since I did report to him, I was still obliged to maintain contact through periodic phone conversations and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ and occasional meetings. During one of those meetings, some 12 months after moving from head office, we talked about the state of the company and his activities over the past year. I'd been hearing stories of his awful ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi management behavior and the deteriorating condition of the whole Canadian operation. His stories of "conquests," conflicts, "housecleaning," and frustrations with the "unbelievable number of idiots out there" confirmed m ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a y worst fears. This guy was a disaster. My initial assessment of him had been, if anything, too charitable. John did me a big favor that afternoon in his office. His complete lack of leadership and subsequent performanc dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod problems confirmed my growing belief in "people power." Since I couldn't in good conscience belong to a management team that had a leader like this guy, I decided it was time for me to move on...I had been contemplating cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin a career move into the training and consulting field. The huge mismatch between John's values and mine gave me the push I needed to take a new look at what was important to me in life and rethink my career direction. A tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen few months later I joined forces with Art McNeil to build The Achieve Group (it became Canada's largest training and consulting firm over the next decade). Later I heard that many of John's leadership chickens (or perhap t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel s turkeys) came home to roost. He was fired. My need to work for an organization with values similar to my own is far from unique. More than half of the 2,300 respondents surveyed at 50 top business schools were willing ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust to take a 10-percent or greater salary reduction to work at a company that had values consistent with their own. And when second-year students were asked to choose among 10 criteria for job selection, the overall choice y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products was "values that are similar to mine" (number one with women; number two with men, after financial compensation). My files continue to fill with studies that show the benefits of values-based leadership. One Boston Coll . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ege study, for example, examined the eight-year performance of 30 "socially conscious" companies. Those companies performed 106% better than their peer group. And according to a report entitled "Round Table on Public an elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip d Private Sector Ethics," produced by the Conference Board of Canada for Public Works and Government Services Canada, "Companies that spend money to develop and enforce a code of ethics will outperform their competitors. tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Six Sigma Tools For Process Control
|